56 results
DEFA14A
GRTX
Galera Therapeutics Inc
27 Apr 20
Additional proxy soliciting materials
7:32am
to access and review all of the important information contained in the proxy materials before voting.
See the reverse side of this notice to obtain proxy … materials and voting instructions.
0000461236_1 R1.0.1.18
Before You Vote
How to Access the Proxy Materials
Proxy Materials Available to VIEW
DEF 14A
GRTX
Galera Therapeutics Inc
27 Apr 20
Definitive proxy
7:30am
(the “Internet Notice”) containing instructions on how to access this proxy statement and our 2019 Annual Report and vote online. If you received an Internet … instructs you on how to access and review all of the important information contained in the proxy statement and 2019 Annual Report. The Internet Notice
8-K
EX-99.1
GRTX
Galera Therapeutics Inc
11 May 23
Galera Reports First Quarter 2023 Financial Results and Recent Corporate
7:11am
expanded its commercial leadership team with the appointment of accomplished pharmaceutical sales, market access, and commercial operations executives … , including Patrick Campbell as Vice President of Sales & Account Management, Elizabeth Turner as Vice President of Market Access, and Henning Thorsen
DRS
EX-4.2
ijco6ck689 o8
15 Mar 19
Draft registration statement
12:00am
S-1
EX-4.2
hwvur01nw
11 Oct 19
IPO registration
5:27pm
8-K
EX-10.0
h8q1noe0rrx46u 2ynp
18 Aug 21
Entry into a Material Definitive Agreement
4:05pm
S-1/A
EX-4.2
2s5lgw14rb7aeylpu
28 Oct 19
IPO registration (amended)
7:16am
S-1
EX-3.2
fxe8tfr
11 Oct 19
IPO registration
5:27pm
DRS
EX-3.2
yehoaxo7f4w5ux
15 Mar 19
Draft registration statement
12:00am
CORRESP
9o51 beblzraez
18 Oct 19
Correspondence with SEC
12:00am
S-3
EX-1.2
n6lw1 uby33lgo6oz13
1 Dec 20
Shelf registration
5:21pm
S-1/A
EX-1.1
fkl0cqvs u4
28 Oct 19
IPO registration (amended)
7:16am
8-K
EX-99.1
3f2acvn7
28 Apr 21
Regulation FD Disclosure
12:00am